Eli Lilly and Company (NYSE:LLY) Given New $1,376.00 Price Target at Truist Financial

Eli Lilly and Company (NYSE:LLY) had its price objective lifted by equities researchers at Truist Financial from $1,370.00 to $1,376.00 in a report released on Friday,Benzinga reports. The firm presently has a “buy” rating on the stock. Truist Financial’s price objective points to a potential upside of 18.17% from the stock’s previous close.

A number of other analysts also recently commented on the stock. Wall Street Zen downgraded shares of Eli Lilly and Company from a “strong-buy” rating to a “buy” rating in a report on Saturday, July 18th. Cantor Fitzgerald lifted their price target on shares of Eli Lilly and Company from $1,350.00 to $1,410.00 and gave the stock an “overweight” rating in a research report on Thursday. Guggenheim upped their price target on Eli Lilly and Company from $1,235.00 to $1,273.00 and gave the company a “buy” rating in a report on Monday, July 13th. Sanford C. Bernstein increased their price objective on Eli Lilly and Company from $1,300.00 to $1,385.00 and gave the company an “outperform” rating in a research report on Tuesday, July 14th. Finally, Bank of America raised their price objective on Eli Lilly and Company from $1,251.00 to $1,334.00 and gave the stock a “buy” rating in a research note on Friday, July 10th. Two research analysts have rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $1,293.93.

Eli Lilly and Company Price Performance

NYSE:LLY opened at $1,164.39 on Friday. The business’s 50-day moving average price is $1,157.76 and its 200 day moving average price is $1,046.57. The firm has a market cap of $1.10 trillion, a P/E ratio of 39.42, a PEG ratio of 1.41 and a beta of 0.51. Eli Lilly and Company has a 52-week low of $623.78 and a 52-week high of $1,249.45. The company has a quick ratio of 1.10, a current ratio of 1.50 and a debt-to-equity ratio of 1.26.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Wednesday, August 5th. The company reported $8.38 earnings per share for the quarter, beating analysts’ consensus estimates of $6.40 by $1.98. Eli Lilly and Company had a net margin of 33.53% and a return on equity of 103.84%. The company had revenue of $22.97 billion during the quarter, compared to the consensus estimate of $20.82 billion. During the same period in the prior year, the company earned $6.31 EPS. Eli Lilly and Company’s revenue was up 47.7% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. As a group, sell-side analysts predict that Eli Lilly and Company will post 36 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Eli Lilly and Company

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in LLY. Osbon Capital Management LLC acquired a new position in Eli Lilly and Company during the fourth quarter valued at $25,000. Basso Capital Management L.P. acquired a new stake in Eli Lilly and Company during the 4th quarter worth about $30,000. Maseco LLP grew its stake in Eli Lilly and Company by 466.7% during the 1st quarter. Maseco LLP now owns 34 shares of the company’s stock valued at $31,000 after acquiring an additional 28 shares in the last quarter. E Fund Management Hong Kong Co. Ltd. increased its holdings in shares of Eli Lilly and Company by 342.9% in the 4th quarter. E Fund Management Hong Kong Co. Ltd. now owns 31 shares of the company’s stock valued at $32,000 after purchasing an additional 24 shares during the period. Finally, Aventus Investment Advisors Inc. increased its holdings in shares of Eli Lilly and Company by 270.0% in the 1st quarter. Aventus Investment Advisors Inc. now owns 37 shares of the company’s stock valued at $34,000 after purchasing an additional 27 shares during the period. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company News Summary

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly reported second-quarter revenue of approximately $22.97 billion, up 47.7% year over year and well above consensus estimates. Adjusted earnings of $8.38 per share also exceeded expectations by a wide margin. Eli Lilly Stock Remains a Buy after Q2
• Positive Sentiment: Mounjaro sales rose 91%, while Mounjaro and Zepbound together generated nearly $15 billion in quarterly revenue. The performance highlights Lilly’s widening advantage in the diabetes and obesity-drug market. Eli Lilly Raises 2026 Outlook Again
• Positive Sentiment: Management raised full-year 2026 revenue guidance to approximately $85 billion–$87 billion from $82 billion–$85 billion and maintained an earnings outlook of $35.50–$36.50 per share. Foundayo adoption, broader Medicare obesity-drug access and international expansion provide additional growth drivers. LLY Q2 Earnings Call Raises Outlook
• Positive Sentiment: Cantor Fitzgerald raised its price target to $1,410 and reiterated an “overweight” rating, reflecting continued Wall Street confidence after the beat-and-raise quarter. Cantor Fitzgerald Raises Eli Lilly Price Target
• Positive Sentiment: Lilly and Novo Nordisk prevailed in an antitrust lawsuit concerning the GLP-1 drug market, removing a potential legal overhang for Lilly’s obesity-treatment business. Lilly and Novo Defeat Antitrust Lawsuit

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.